N,N'-dimethyl-N'-phenylpropane-1,3-diamine | 150758-75-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N'-dimethyl-N'-phenylpropane-1,3-diamine
• CAS: 150758-75-1
• 化学式: C₁₁H₁₈N₂
• mdl: MFCD11151628
• 分子量: 178.277
• InChiKey: JSGDEZVECUMWQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N'-dimethyl-N'-phenylpropane-1,3-diamine 、 6-(2,3-epoxypropoxy)-2(1H)-quinolinone 以 甲醇 为溶剂， 反应 3.0h， 生成 6-[2-hydroxy-3-[methyl-[3-(N-methylanilino)propyl]amino]propoxy]-1H-quinolin-2-one
  参考文献：
  名称：

  Novel positive inotropic agents: synthesis and biological activities of 6-(3-amino-2-hydroxypropoxy)-2(1H)-quinolinone derivatives

  摘要：

  A series of 6-(3-amino-2-hydroxypropoxy)-2(1H)-quinolinones has been synthesized and evaluated for positive inotropic activity on the canine heart. Some of these derivatives have a potent activity with none or negative chronotropic effect in isolated, blood-perfused dog heart preparations. They also display a high selectivity for positive inotropic effect over chronotropic and vasodilatory effects in anesthetized dogs. (+/-)-6-[2-Hydroxy-3-[(3-methoxybenzyl)amino]propoxy]-2(1H)-quinolinone (39) and (+/-)-6-[3-(3,4-dimethoxybenzyl)amino]-2-hydroxypropoxy]-2(1H)-quinolinone (40) were further investigated in conscious dogs. After iv administration, they did not affect heart rate or mean blood pressure at the dose producing a 50% increase in the peak of the first derivative of the left ventricular pressure. The compounds (39,OPC-18750, and 40,OPC-18790) are the most promising agents with desirable biological activities, and now are currently undergoing clinical evaluation.

  DOI：

  10.1021/jm00098a003
• 作为产物：
  描述：

  3-methyl-1,3-oxazinan-2-one 、 N-甲基苯胺 以70%的产率得到
  参考文献：
  名称：

  Poindexter Graham S., Strauss Karen M., Synth. Commun., 23 (1993) N 9, S 1329-1338

  摘要：

  DOI：

文献信息

• PROCESS FOR PRODUCING MACROLIDE COMPOUND AND INTERMEDIATE THEREFOR
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2168961A1

  公开（公告）日：2010-03-31

  The present invention provides a method for producing a 12-membered ring macrolide compound expected as a prophylactic or therapeutic agent for solid tumors and the like, and a production intermediate thereof. In detail, by acetalizing hydroxyl groups at 6- and 7-positions of a 12-membered ring macrolide compound being a raw material with dialkyl tin (IV) oxide and, after that, reacting the product with a carbamoyl halide derivative, the 7-position urethane derivative of the 12-membered ring macrolide compound being the target is effectively produced, without protecting hydroxyl groups at other positions.

  本发明提供了一种生产预期作为固体肿瘤等疾病的预防或治疗剂的12元环大环内酯化合物的方法，以及其生产中间体。具体而言，通过将作为原料的12元环大环内酯化合物的6-和7-位置的羟基与二烷基锡（IV）氧化物缩醛化，然后将产物与氨基甲酰卤衍生物反应，有效地生产了目标为12元环大环内酯化合物的7-位置脲酯衍生物，而无需保护其他位置的羟基。
• Novel physiologically active substances
  申请人：Kotake Yoshihiko

  公开号：US20050245514A1

  公开（公告）日：2005-11-03

  Compounds represented by the following general formula (I), pharmacologically acceptable salts thereof or hydrates of the same: (I) wherein W represents and R 3 , R 7 , R 16 , R 17 , R 20 , R 21 and R 21′ are the same or different and each represents hydrogen, etc. Because of inhibiting angiogenesis and inhibiting the production of VEGF particularly in hypoxia, the compounds (I) are useful as remedies for solid cancer.

  具有下述通式(I)表示的化合物、其药理学上可接受的盐或水合物：(I)其中W代表，R3、R7、R16、R17、R20、R21及R21'相同或不同，各自代表氢等。由于能抑制血管生成及在缺氧条件下抑制VEGF的产生，化合物(I)可作为实体癌症的治疗药物。
• 12 MEMBERED-RING MACROLACTAM DERIVATIVES
  申请人：Miyano Masayuki

  公开号：US20080312317A1

  公开（公告）日：2008-12-18

  There provided a 12-membered-ring macrolactam derivative having antitumor activity: A compound represented by Formula (1) or a salt thereof. In this Formula, R 1 is a hydrogen atom, a C 1-6 alkyl group, a C 1-6 alkylcarbonyl group or a C 6-14 arylcarbonyl group; R 2 is a hydrogen atom or a C 1-6 alkyl group; R 3 is a hydrogen atom or a hydroxyl group; R 4 is a hydrogen atom or a hydroxyl group; R 5 is a hydrogen atom or a C 1-6 alkyl group; R 6 is a hydrogen atom or a hydroxyl group; and R 7 is an acetyl group or the like.

  提供了一种具有抗肿瘤活性的12-成员环大环内酰胺衍生物：由化学式（1）表示的化合物或其盐。在该化学式中，R1是氢原子、C1-6烷基基团、C1-6烷基羰基基团或C6-14芳基羰基基团；R2是氢原子或C1-6烷基基团；R3是氢原子或羟基；R4是氢原子或羟基；R5是氢原子或C1-6烷基基团；R6是氢原子或羟基；R7是乙酰基或类似物。
• [EN] METHODS OF MODULATING CFTR ACTIVITY<br/>[FR] PROCÉDÉS DE MODULATION DE L'ACTIVITÉ DE CFTR
  申请人：PROTEOSTASIS THERAPEUTICS INC

  公开号：WO2014210159A1

  公开（公告）日：2014-12-31

  The invention encompasses methods of modulating CFTR activity in a subject in need thereof comprising administering an effective amount of a compound of Formula (I). The invention also encompasses methods of treating a condition associated with CFTR activity or condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a compound of Formula (I).

  这项发明涵盖了在需要的受试者中调节CFTR活性的方法，包括向受试者施用化合物Formula (I)的有效量。该发明还涵盖了治疗与CFTR活性相关的疾病或与蛋白质稳态功能障碍相关的疾病的方法，包括向受试者施用化合物Formula (I)的有效量。
• PYRIMIDINE COMPOUND
  申请人：Matsushima Yuji

  公开号：US20110053912A1

  公开（公告）日：2011-03-03

  A novel and excellent method for preventing and/or treating diseases related to a cannabinoid type 2 receptor, based on an agonistic action on a cannabinoid type 2 receptor. It was found that a hetero ring derivative mainly having two substituents, for example, a pyrimidine-5-carboxamide derivative having a substituent amino group at the 2-position, exhibits a potent agonistic action on a cannabinoid type 2 receptor, and can be an agent for preventing and/or treating diseases related to a cannabinoid type 2 receptor such as inflammatory diseases, pain, and the like.

  一种预防和/或治疗与大麻素2型受体相关疾病的新颖优秀方法，基于对大麻素2型受体的激动作用。发现一种异核环衍生物主要具有两个取代基，例如，在2-位置具有取代基氨基的嘧啶-5-羧酰胺衍生物，表现出对大麻素2型受体的强效激动作用，可以成为预防和/或治疗与大麻素2型受体相关疾病，如炎症性疾病、疼痛等的药物。